Concepedia

Victoria L. Peek

VL

8

Publications

606

Citations

8

H-Index

2005

Active since

Affiliations

Eli Lilly (United States)(Current)

Victoria L. Peek is an author at Eli Lilly (United States) specializing in cancer therapeutics, pharmacotherapy, and tumor biology.

Top concepts

Publications per year

2005–2018

8

Publications

8

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

S. Betty Yan, Victoria L. Peek, Rose T. Ajamie et al. · Investigational New Drugs · 2012 · 159 citations · Full text

Akt Activation, but not Extracellular Signal–Regulated Kinase Activation, Is Required for SDF-1α/CXCR4–Mediated Migration of Epitheloid Carcinoma Cells

Sheng-Bin Peng, Victoria L. Peek, Yan Zhai et al. · Molecular Cancer Research · 2005 · 107 citations

LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth

Ling Liu, Wei Zeng, Mark A. Wortinger et al. · Clinical Cancer Research · 2014 · 105 citations

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Wenjuan Wu, Bi Chen, Kelly M. Credille et al. · Clinical Cancer Research · 2013 · 67 citations · Full text

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Bruce W. Konicek, Andrew Capen, Kelly M. Credille et al. · Oncotarget · 2018 · 49 citations · Full text

Rows per page

1–5 of 8